Navigation Links
InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
Date:6/10/2009

LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain.

The 4 week double blind placebo controlled study of INT131 in Type 2 Diabetes Mellitus (T2DM) patients previously not on pharmacological therapy showed a dose dependent decrease in fasting plasma glucose (FPG) at 4 weeks, the primary endpoint of the study. This decrease was already statistically significant at 1 week for both low and high doses (1 mg and 10 mg) of INT131.

The efficacy measured at 4 weeks of 1 mg of INT131 treatment was comparable to the efficacy modeled for this patient population treated with the maximal approved doses of Actos(R) and Avandia(R), but in contrast the low dose INT131 group did not show the significant weight gain or fluid retention (measured by hematocrit drop) modeled for maximal dose TZDs. The high dose INT131 group showed about twice the decrease in FPG attained with low dose INT131, and a correspondingly greater efficacy compared to that modeled for maximal dose TZDs. Importantly, this greater efficacy was achieved with INT131 without greater weight gain or hematocrit drop than expected for maximal dose TZDs. INT131 was well tolerated in this study with no safety issues noted.

"These data are supportive of INT131 acting as a selective modulator of PPARgamma in T2DM patients," remarked Dr Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, who presented the data. "The key observation from this study is that INT131 is a potent insulin sensitizer that lowers fasting glucose as well as the maximal dose of the TZDs while mitigating the typical side effect profile."

"Transla
'/>"/>

SOURCE InteKrin Therapeutics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. InteKrin Therapeutics Announces $20 Million Series C Financing
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
4. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
5. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
6. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
7. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
8. Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
9. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
10. Cephalon Acquires Controlling Interest in Arana Therapeutics
11. Cornerstone Therapeutics Announces Management Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... July 12, 2014 Demand Response Management ... considerable benefits in reducing the imbalance between energy supply ... appliances have been rolled out (due to increasing pressure ... (AMI). This helps in controlling residential appliances and thermostats ... in the North American region, and with government mandates ...
(Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... 12, 2014 “Critical Care Therapeutics ... and Late-Stage Four-Factor PCCs and Recombinant Products to ... critical care market in the US, UK, France, ... provides an estimation of market size for 2013, ... critical care indications that are being treated using ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... as 10-fold, researchers find, , MONDAY, Sept. 7 (HealthDay ... minor infection can double the rate of memory loss, ... found that Alzheimer,s patients who had respiratory, gastrointestinal or ... can have high levels of tumor necrosis factor-alpha (TNF-a), ...
... minor complications seen with ,after-hours, procedures, study finds , ... daytime slot to undergo an orthopedic procedure may lower ... a new study has found. , The study, ... of Bone and Joint Surgery , found little difference ...
... 7 Bounty, the UK,s favourite parenting,club, today launches a 4 ... mums take a real life, close up peek at how a ... To view the Multimedia News Release, please click: , ... Breastfeeding is the healthiest and most natural way to feed a ...
... , , , ... Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell ... its breakthrough stem cell and related technology. The Jordanian Stem ... purchase the technology from Stemedica,s wholly-owned subsidiary, Stemedica International, S.A. ...
... in clearance of amyloid plaque from brain , SUNDAY, ... scientists have uncovered three gene variants that up the ... dementia among the elderly and the seventh-leading cause of ... Dr. Philippe Amouyel of the Institut Pasteur de Lille ...
... ... the grand opening of the new rehabilitation hospital with partner HealthSouth. , ... Mesa, Ariz. (PRWEB) September 6, ... on August 18 to welcome the rehabilitation hospital to the East Valley and ...
Cached Medicine News:Health News:Even Mild Infections Hasten Decline With Alzheimer's 2Health News:Even Mild Infections Hasten Decline With Alzheimer's 3Health News:Let Orthopedic Surgery Wait Until Morning When Possible 2Health News:Bounty Parenting Club Launches View on Demand 'How to Breastfeed' Video 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 3Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 2Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 3Health News:ATSU Arizona Health & Technology Park Partner HealthSouth Holds Grand Opening 2
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Pro Osteon Bone Graft Substitutes a natural ... from cadaver bone, but such grafts may ... disease transmission. Interpore Cross has developed the ... to address these needs, offering surgeons a ...
... Healos is an osteoconductive matrix constructed ... fully coated with hydroxyapatite through a ... with autogenous bone marrow aspirate, Healos ... cell attachment, proliferation and differentiation. The ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Sharp Weitlaner Retractor....
Medicine Products: